Cost-Effectiveness of Interferon-α and Conventional Chemotherapy in Chronic Myelogenous Leukemia

Annals of Internal Medicine

Volumn 125, Issue 7, 1996, Pages 541-548

  Kattan, Michael W ^a   Inoue, Yuji ^b   Giles, Francis J ^c   Talpaz, Moshe ^d   Ozer, Howard ^e   Guilhot, Francois ^f   Zuffa, Eliana ^g   Huber, Stephen L ^d   Beck, J Robert ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b YAMAGUCHI UNIVERSITY   (Japan)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e EMORY UNIVERSITY   (United States)

^f POITIERS UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; HYDROXYUREA;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; HUMAN; META ANALYSIS; MIDDLE AGED; MULTICENTER STUDY; MYELOID LEUKEMIA; PROBABILITY; QUALITY ADJUSTED LIFE YEAR;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC-PHASE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 0030268399     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-7-199610010-00002     Document Type: Article

References (26)

1. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med. 1988;319:990-8.
2. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood. 1993;82: 398-407.
3. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med. 1994;330:820-5.
4. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet. 1996;345:1392-7.
5. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival. Cancer and Leukemia Group B study 8583. Blood. 1993;82:2975-84.
6. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med. 1995;122:254-61.
7. Bilhou-Nabera C, Viard F, Marit G, Gharbi MJ, Salzes S, Reiffers J, et al. Complete cytogenetic conversion in chronic myelocytic leukemia patients undergoing interferon alpha therapy: follow-up with reverse polymerase chain reaction. Leukemia. 1992;6:595-8.
8. + chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia Haematologica. 1992;77:204-14.
9. Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med. 1987;83:445-54.
10. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-38.
11. Giralt SA, Kantarjian HM, Talpaz M, Rios MB, Del Giglio A, Andersson BS, et al. Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol. 1993;11:1055-61.
12. National Center for Health Statistics. Vital Statistics of the United States, 1988. v. II. Mortality, Part A. DHHS publication no. (PHS) 95-1104. Washington, DC: Public Health Services; 1991.
13. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectivness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med. 1995;122:664-75.
14. Hjorth M, Westin J, Dahl IM, Gimsing P, Hippe E, Holmberg E, et al. Interferon-α2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. Ann Intern Med. 1996;124:212-22.
15. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol. 1995;13:2401-7.
16. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia. A concise update. Blood. 1993;82:591-703.
17. Sobocinski, KA, Horowitz MM, Rowlings PA, Zhang MJ, Nugent ML, Passweg JR, et al. Bone marrow transplantation - 1994: a report from the International Bone Marrow Transplant Registry and the North American Autologous Bone Marrow Transplant Registry. J Hematother. 1994;3:95-102.
18. Stipp D. Prevention may be costlier than a cure. Wall Street Journal. 6 July 1994;B:1.
19. Byers T, Gorsky R. Estimates of costs and effects of screening for colorectal cancer in the United States. Cancer. 1992;70:1288-95.
20. Smith TJ, Hillner BE. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol. 1993;11: 771-6.
21. Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. JAMA. 1992;267: 2055-61.
22. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol. 1994;89:670-80.
23. Desch CE, Lasala MR, Smith TJ, Hillner BE. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol. 1992;10:200-9.
24. Feldman S, Berkowitz RZ, Tosteson AN. Cost-effectiveness of strategies to evaluate postmenopausal bleeding. Obstet Gynecol. 1993;81:968-75.
25. Schofield JR, Robinson WA, Murphy JR, Rovira DK. Low doses of interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med. 1994;121:736-44.
26. Nord E. Methods for quality adjustment of life years. Soc Sci Med. 1992;94: 560-6.